The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
India in the Changing Landscape of Life-Sciences Research & Development
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
Subscribe To Our Newsletter & Stay Updated
